HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
bidisomide
RN given refers to parent cpd
Also Known As:
SC 40230; SC-40230; alpha-(2-(acetyl(1-methylethyl)amino)ethyl)-alpha-(2-chlorophenyl)-1-piperidinebutanamide; bidisomide, (+)-isomer; bidisomide, (+-)-isomer; bidisomide, (-)-isomer
Networked:
6
relevant articles (
2
outcomes,
1
trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Heterocyclic Compounds: 198
1-Ring Heterocyclic Compounds
Piperidines: 17
bidisomide: 6
Related Diseases
1.
Atrial Fibrillation
10/21/1997 - "
Among the atrial fibrillation patients, there was no significant difference in the time to first symptomatic recurrence between the placebo group and any of the three bidisomide treatment groups; the hazard ratios (placebo:treatment) were 1.19, 1.03, and 1.14 for bidisomide 200, 400, and 600 mg BID, respectively.
"
10/21/1997 - "
The Atrial Fibrillation Investigation with Bidisomide (AFIB) Investigators.
"
10/21/1997 - "
Treatment of atrial fibrillation and paroxysmal supraventricular tachycardia with bidisomide.
"
10/21/1997 - "
The Atrial Fibrillation Investigation with Bidisomide (AFIB) study was a randomized, placebo-controlled clinical trial designed to accomplish three goals in a single protocol: (1) to determine the efficacy of the antiarrhythmic drug bidisomide in the treatment of these two arrhythmias; (2) to establish the appropriate dose range for bidisomide; and (3) to detect an adverse mortality effect of bidisomide if one were present in patients with atrial fibrillation.
"
10/21/1997 - "
In this clinical trial, 1227 patients with atrial fibrillation and 187 with paroxysmal supraventricular tachycardia were randomly assigned to bidisomide (200, 400, or 600 mg BID) or placebo; patient groups with each arrhythmia were analyzed separately.
"
2.
Cardiac Arrhythmias (Arrythmia)
02/17/1993 - "
Bidisomide suppressed these three arrhythmia models.
"
02/17/1993 - "
Effects of a new class I antiarrhythmic drug bidisomide on canine ventricular arrhythmia models.
"
10/21/1997 - "
In this clinical trial, 1227 patients with atrial fibrillation and 187 with paroxysmal supraventricular tachycardia were randomly assigned to bidisomide (200, 400, or 600 mg BID) or placebo; patient groups with each arrhythmia were analyzed separately.
"
02/17/1993 - "
The antiarrhythmic plasma concentration, IC50, of bidisomide for digitalis-induced arrhythmia was 22.1 micrograms/ml, and those calculated for intravenous bidisomide in 24 h and 48 h coronary ligation-arrhythmias were 15.1 and 11.6 micrograms/ml and that calculated for oral bidisomide in 24 h coronary ligation-arrhythmia was 5.4 micrograms/ml and that for adrenaline induced arrhythmia was 58.7 micrograms/ml. In the blood perfused sinoatrial node and papillary muscle preparations, bidisomide decreased the sinoatrial rate and contractile force and increased the intraventricular conduction time and coronary blood flow.
"
12/01/1989 - "
The class I agents other than lidocaine were almost uniformly effective in terminating the arrhythmia (disopyramide in six of seven dogs, propafenone in six of six, flecainide in seven of seven, and SC-40230 in seven of seven).
"
3.
Ventricular Tachycardia
10/21/1997 - "
Among paroxysmal supraventricular tachycardia patients, there was a similar lack of a significant treatment effect; the hazard ratios were 1.30, 1.93, and 1.59 for bidisomide 200, 400, and 600 mg BID, respectively.
"
10/21/1997 - "
Treatment of atrial fibrillation and paroxysmal supraventricular tachycardia with bidisomide.
"
01/01/1995 - "
Bidisomide (5 mg/kg) reduced the number of premature ventricular complexes and the incidence of ventricular tachycardia and ventricular fibrillation similarly to MXT and DSP in rats with ventricular arrhythmias induced by coronary artery occlusion.
"
10/21/1997 - "
In this clinical trial, 1227 patients with atrial fibrillation and 187 with paroxysmal supraventricular tachycardia were randomly assigned to bidisomide (200, 400, or 600 mg BID) or placebo; patient groups with each arrhythmia were analyzed separately.
"
4.
Myocardial Infarction
02/01/1993 - "
The effect of bidisomide (SC-40230), a new class Ia/Ib antiarrhythmic agent, on defibrillation energy requirements in dogs with healed myocardial infarctions.
"
08/01/1992 - "
The acute tolerability of rapid infusions of bidisomide or disopyramide was evaluated in normal conscious dogs and in conscious dogs 48 h after the creation of myocardial infarctions (MIs).
"
08/01/1992 - "
Rapid infusions of bidisomide or disopyramide in conscious dogs: effect of myocardial infarction on acute tolerability.
"
5.
Infarction (Infarctions)
02/01/1993 - "
The potential for bidisomide to increase defibrillation threshold (DFT) was tested in anesthetized dogs with healed left ventricular infarcts (> or = 10 days).
"
08/01/1992 - "
Bidisomide (15 mg/kg/min) was well tolerated and antiarrhythmic in dogs with infarctions.
"
08/01/1992 - "
Both bidisomide and disopyramide shifted the mean electrical axis of the QRS complex from a right axis deviation to the normal range in dogs with infarctions.
"
Related Drugs and Biologics
1.
Anti-Arrhythmia Agents
2.
Disopyramide (Norpace)
3.
Propafenone (Rythmol)
4.
Lidocaine (Xylocaine)
5.
Flecainide (Tambocor)
6.
Epinephrine (Adrenaline)
Related Therapies and Procedures
1.
Ligation